FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1922104457> ?p ?o ?g. }

• W1922104457 endingPage "1371" @default.
• W1922104457 startingPage "1360" @default.
• W1922104457 abstract "Effective treatments for primary brain tumors and brain metastases represent a major unmet medical need. Targeting the CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway using a potent CDK4 and CDK6 kinase inhibitor has potential for treating primary central nervous system tumors such as glioblastoma and some peripheral tumors with high incidence of brain metastases. We compared central nervous system exposures of two orally bioavailable CDK4 and CDK6 inhibitors: abemaciclib, which is currently in advanced clinical development, and palbociclib (IBRANCE; Pfizer), which was recently approved by the U.S. Food and Drug Administration. Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ). Both inhibitors were substrates for xenobiotic efflux transporters P-glycoprotein and breast cancer resistant protein expressed at the blood-brain barrier. Brain Kp,uu values were less than 0.2 after an equimolar intravenous dose indicative of active efflux but were approximately 10-fold greater for abemaciclib than palbociclib. Kp,uu increased 2.8- and 21-fold, respectively, when similarly dosed in P-gp-deficient mice. Abemaciclib had brain area under the curve (0-24 hours) Kp,uu values of 0.03 in mice and 0.11 in rats after a 30 mg/kg p.o. dose. Orally dosed abemaciclib significantly increased survival in a rat orthotopic U87MG xenograft model compared with vehicle-treated animals, and efficacy coincided with a dose-dependent increase in unbound plasma and brain exposures in excess of the CDK4 and CDK6 Ki values. Abemaciclib increased survival time of intracranial U87MG tumor-bearing rats similar to TMZ, and the combination of abemaciclib and TMZ was additive or greater than additive. These data show that abemaciclib crosses the blood-brain barrier and confirm that both CDK4 and CDK6 inhibitors reach unbound brain levels in rodents that are expected to produce enzyme inhibition; however, abemaciclib brain levels are reached more efficiently at presumably lower doses than palbociclib and are potentially on target for a longer period of time." @default.
• W1922104457 created "2016-06-24" @default.
• W1922104457 creator A5011111962 @default.
• W1922104457 creator A5012620497 @default.
• W1922104457 creator A5021489070 @default.
• W1922104457 creator A5022761123 @default.
• W1922104457 creator A5054052513 @default.
• W1922104457 creator A5055899487 @default.
• W1922104457 creator A5065087121 @default.
• W1922104457 creator A5065902063 @default.
• W1922104457 creator A5079629521 @default.
• W1922104457 creator A5081828223 @default.
• W1922104457 date "2015-07-06" @default.
• W1922104457 modified "2023-10-18" @default.
• W1922104457 title "Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft" @default.
• W1922104457 cites W137179722 @default.
• W1922104457 cites W1886326176 @default.
• W1922104457 cites W1965785026 @default.
• W1922104457 cites W1969255091 @default.
• W1922104457 cites W1977253304 @default.
• W1922104457 cites W1980884243 @default.
• W1922104457 cites W1990250882 @default.
• W1922104457 cites W1991601194 @default.
• W1922104457 cites W1994761603 @default.
• W1922104457 cites W1995632100 @default.
• W1922104457 cites W1996963479 @default.
• W1922104457 cites W2005447377 @default.
• W1922104457 cites W2007618242 @default.
• W1922104457 cites W2009927285 @default.
• W1922104457 cites W2018023615 @default.
• W1922104457 cites W2020217107 @default.
• W1922104457 cites W2023553115 @default.
• W1922104457 cites W2024636481 @default.
• W1922104457 cites W2025183726 @default.
• W1922104457 cites W2026974006 @default.
• W1922104457 cites W2027517328 @default.
• W1922104457 cites W2034277114 @default.
• W1922104457 cites W2038349110 @default.
• W1922104457 cites W2040827479 @default.
• W1922104457 cites W2049517140 @default.
• W1922104457 cites W2051651821 @default.
• W1922104457 cites W2054976145 @default.
• W1922104457 cites W2055475004 @default.
• W1922104457 cites W2058780134 @default.
• W1922104457 cites W2064670731 @default.
• W1922104457 cites W2077029264 @default.
• W1922104457 cites W2080570608 @default.
• W1922104457 cites W2080571938 @default.
• W1922104457 cites W2082843436 @default.
• W1922104457 cites W2083336965 @default.
• W1922104457 cites W2090945807 @default.
• W1922104457 cites W2095265260 @default.
• W1922104457 cites W2101364181 @default.
• W1922104457 cites W2102513746 @default.
• W1922104457 cites W2108147692 @default.
• W1922104457 cites W2110057699 @default.
• W1922104457 cites W2110604363 @default.
• W1922104457 cites W2111834967 @default.
• W1922104457 cites W2118044926 @default.
• W1922104457 cites W2119874496 @default.
• W1922104457 cites W2119997685 @default.
• W1922104457 cites W2126799977 @default.
• W1922104457 cites W2128527026 @default.
• W1922104457 cites W2131558896 @default.
• W1922104457 cites W2133802199 @default.
• W1922104457 cites W2136158663 @default.
• W1922104457 cites W2142075003 @default.
• W1922104457 cites W2143535850 @default.
• W1922104457 cites W2148365177 @default.
• W1922104457 cites W2153030337 @default.
• W1922104457 cites W2156726305 @default.
• W1922104457 cites W2157005154 @default.
• W1922104457 cites W2162065895 @default.
• W1922104457 cites W2167077512 @default.
• W1922104457 cites W2168161641 @default.
• W1922104457 cites W2169004576 @default.
• W1922104457 cites W2170431872 @default.
• W1922104457 cites W958201417 @default.
• W1922104457 doi "https://doi.org/10.1124/dmd.114.062745" @default.
• W1922104457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26149830" @default.
• W1922104457 hasPublicationYear "2015" @default.
• W1922104457 type Work @default.
• W1922104457 sameAs 1922104457 @default.
• W1922104457 citedByCount "200" @default.
• W1922104457 countsByYear W19221044572015 @default.
• W1922104457 countsByYear W19221044572016 @default.
• W1922104457 countsByYear W19221044572017 @default.
• W1922104457 countsByYear W19221044572018 @default.
• W1922104457 countsByYear W19221044572019 @default.
• W1922104457 countsByYear W19221044572020 @default.
• W1922104457 countsByYear W19221044572021 @default.
• W1922104457 countsByYear W19221044572022 @default.
• W1922104457 countsByYear W19221044572023 @default.
• W1922104457 crossrefType "journal-article" @default.
• W1922104457 hasAuthorship W1922104457A5011111962 @default.
• W1922104457 hasAuthorship W1922104457A5012620497 @default.
• W1922104457 hasAuthorship W1922104457A5021489070 @default.
• W1922104457 hasAuthorship W1922104457A5022761123 @default.

• next